CA3106108A1 - Compositions and methods related to engineered fc-antigen binding domain constructs targeted to pd-l1 - Google Patents

Compositions and methods related to engineered fc-antigen binding domain constructs targeted to pd-l1 Download PDF

Info

Publication number
CA3106108A1
CA3106108A1 CA3106108A CA3106108A CA3106108A1 CA 3106108 A1 CA3106108 A1 CA 3106108A1 CA 3106108 A CA3106108 A CA 3106108A CA 3106108 A CA3106108 A CA 3106108A CA 3106108 A1 CA3106108 A1 CA 3106108A1
Authority
CA
Canada
Prior art keywords
domain
polypeptide
monomer
domain monomer
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3106108A
Other languages
English (en)
French (fr)
Inventor
Laura RUTITZKY
Jonathan C. Lansing
Daniel ORTIZ
Anthony Manning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Momenta Pharmaceuticals Inc
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of CA3106108A1 publication Critical patent/CA3106108A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3106108A 2018-07-11 2019-07-11 Compositions and methods related to engineered fc-antigen binding domain constructs targeted to pd-l1 Pending CA3106108A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862696711P 2018-07-11 2018-07-11
US62/696,711 2018-07-11
PCT/US2019/041306 WO2020014419A2 (en) 2018-07-11 2019-07-11 Compositions and methods related to engineered fc-antigen binding domain constructs targeted to pd-l1

Publications (1)

Publication Number Publication Date
CA3106108A1 true CA3106108A1 (en) 2020-01-16

Family

ID=69141681

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3106108A Pending CA3106108A1 (en) 2018-07-11 2019-07-11 Compositions and methods related to engineered fc-antigen binding domain constructs targeted to pd-l1

Country Status (11)

Country Link
US (1) US20210147549A1 (cg-RX-API-DMAC7.html)
EP (1) EP3820998A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021530989A (cg-RX-API-DMAC7.html)
KR (1) KR20210044782A (cg-RX-API-DMAC7.html)
CN (1) CN112996910A (cg-RX-API-DMAC7.html)
AU (1) AU2019299935A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021000383A2 (cg-RX-API-DMAC7.html)
CA (1) CA3106108A1 (cg-RX-API-DMAC7.html)
IL (1) IL280038A (cg-RX-API-DMAC7.html)
MX (1) MX2021000281A (cg-RX-API-DMAC7.html)
WO (1) WO2020014419A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024219897A1 (ko) * 2023-04-21 2024-10-24 상트네어바이오사이언스 주식회사 두 개의 fab 도메인 및 두 개의 fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도
TW202504932A (zh) * 2023-04-21 2025-02-01 南韓商百歲生命科學股份有限公司 包含兩個fc區域之抗原結合蛋白及其用途
CN117736329B (zh) * 2023-12-25 2024-11-12 华润生物医药有限公司 抗pd-1抗体及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014012819B1 (pt) * 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
MX360056B (es) * 2012-03-08 2018-10-19 Janssen Vaccines & Prevention Bv Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos.
US20150203591A1 (en) * 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
SG10201913507SA (en) * 2014-05-02 2020-02-27 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
CA2972800A1 (en) * 2015-01-02 2016-07-07 Dyax Corp. Bispecific antibodies against plasma kallikrein and factor xii
US9512229B2 (en) * 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
RU2766890C2 (ru) * 2015-06-16 2022-03-16 Мерк Патент Гмбх Комбинированные способы лечения антагонистами pd-l1
JP2018529719A (ja) * 2015-09-30 2018-10-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Alk陰性がんを処置するためのpd−1系結合アンタゴニストおよびalk阻害剤の組合せ
CN106939047B (zh) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
US12391759B2 (en) * 2016-03-02 2025-08-19 Momenta Pharmaceuticals, Inc. Methods related to engineered Fc constructs
JP7080213B2 (ja) * 2016-03-23 2022-06-03 スーチョウ トランセンタ セラピューティクス カンパニー,リミテッド 新規抗pd-l1抗体
IL309293A (en) * 2016-05-23 2024-02-01 Momenta Pharmaceuticals Inc Compositions and methods relating to engineered FC constructs
EP3507367A4 (en) * 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
EP3559032A1 (en) * 2016-12-23 2019-10-30 Innate Pharma Heterodimeric antigen binding proteins

Also Published As

Publication number Publication date
JP2021530989A (ja) 2021-11-18
WO2020014419A3 (en) 2020-02-20
WO2020014419A2 (en) 2020-01-16
BR112021000383A2 (pt) 2021-04-06
AU2019299935A1 (en) 2021-02-18
US20210147549A1 (en) 2021-05-20
MX2021000281A (es) 2021-11-12
EP3820998A2 (en) 2021-05-19
KR20210044782A (ko) 2021-04-23
EP3820998A4 (en) 2022-04-27
WO2020014419A8 (en) 2021-12-02
CN112996910A (zh) 2021-06-18
IL280038A (en) 2021-03-01

Similar Documents

Publication Publication Date Title
US20220064298A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CTLA-4
EP3565595A1 (en) Compositions and methods related to engineered fc-antigen binding domain constructs
US20220267460A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
US20210269546A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CD38
US20210317227A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
US20210147549A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO PD-L1
US20250346676A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CCR4
EP3820523A1 (en) Compositions and methods related to engineered fc-antigen binding domain constructs
CA3106254A1 (en) Compositions and methods related to engineered fc-antigen binding domain constructs
EP4031166A1 (en) Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38